scholarly journals Association of theMDM2SNP285 Polymorphism with Cancer Susceptibility: A Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Ping Wang ◽  
Meilin Wang ◽  
Sanqiang Li ◽  
Lingjun Ma ◽  
Shoumin Xi ◽  
...  

Themouse double minute 2(MDM2) gene encodes a negative regulator for p53, and the polymorphism SNP285 in the promoter region ofMDM2gene has been implicated in cancer risk, but individual published studies had inconclusive results. Therefore, we performed this meta-analysis to obtain a more precise estimation betweenMDM2SNP285 polymorphism and risk of cancer. A systematic literature search was performed using the PubMed, Embase, and Chinese Biomedical (CBM) databases. Ultimately, 16 published studies comprising 14,573 cases and 9,115 controls were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the strength of associations. Overall,MDM2SNP285 polymorphism was significantly associated with a decreased overall cancer risk with the heterozygous model (OR = 0.89, 95% CI = 0.79–0.99), and reduced ORs were observed with other genetic models (dominant: OR = 0.90, 95% CI = 0.79–1.01 and allele comparison: OR = 0.91, 95% CI = 0.80–1.03) but not reaching statistical significance. Stratification analysis indicated a decreased risk for ovarian cancer, Caucasians, and studies with relatively large sample size. Despite some limitations, this meta-analysis indicated that theMDM2SNP285 polymorphism was associated with a decreased cancer risk, which warrants further validation in large and well-designed studies.

PeerJ ◽  
2016 ◽  
Vol 4 ◽  
pp. e1724 ◽  
Author(s):  
Wenbo Zhu ◽  
Jun Zhao ◽  
Jieyu He ◽  
Daxun Qi ◽  
Lina Wang ◽  
...  

The effects of the microRNA (miRNA) processing genes Gemin3 and Gemin4 on cellular signaling pathways could have a major impact on the risk of cancer. Several studies concerning the association between the Gemin3 rs197412, Gemin4 rs7813 and Gemin4 rs2740348 polymorphisms with cancer susceptibility have been published. The present meta-analysis summarized this evidence and evaluated the precision of these relationships. Relevant studies (published prior to December 16th, 2015) without language restriction were identified using the PubMed, Web of Science and China National Knowledge Infrastructure (CNKI) on-line databases. The data were extracted from the eligible studies and were processed using Stata 12.0 software. Seven studies (2,588 cases and 2,549 controls) indicated that the rs7813 polymorphism was significantly associated with increased cancer risk (TT vs TC + CC, OR = 1.18 95% CI [1.05–1.32]). Six studies (1,314 cases and 1,244 controls) indicated that rs2740348 was associated with an increased cancer risk (GG vs. GC + CC, OR = 1.41 95% CI [1.00–1.83]). However the rs197412 polymorphism was not associated with an increased cancer risk (OR = 0.97 95% CI [0.80–1.19]). Our results suggest that the Gemin4 rs7813 T > C and rs2740348 G > C polymorphisms are associated with cancer susceptibility.


2020 ◽  
Author(s):  
Lei Zheng ◽  
Lijuan Rong ◽  
Zhenyun Cheng

Abstract Background: LncRNA metastasis associated with lung adenocarcinoma transcript-1 (MALAT1) was involved in pathogenesis and progress of diverse cancers. To investigate the association of MALAT1 and cancer susceptibility, this meta-analysis was appraised.Methods: 12 studies including 7007 cancer patients and 8791 controls were selected for this meta-analysis. Ratio radiation (ORS) and 95% confidence interval (CIS) were used to assess cancer susceptibility.Results: There was no significant association between rs3200401 polymorphism and the risk of cancer. However, rs3200401 was correlated with an increased risk of digestive cancer in allelic model (OR=1.15, 95%CI=1.04-1.28, P=0.009) and dominant model (OR=1.16, 95%CI=1.02-1.31, P=0.02). There was a borderline association between rs664589 and cancer susceptibility under the dominant model (OR=1.17, 95%CI=1.00-1.38, P=0.05). Rs619586 was associated with decreased cancer risk in all populations under four models (G vs A: OR=0.86, 95%CI=0.78-0.94, P=0.001; GG vs AA: OR=0.60, 95%CI=0.42-0.84, P=0.003; GG+AG vs AA: OR=0.87, 95%CI=0.78-0.97, P=0.009; GG vs AG+AA: OR=0.61, 95%CI=0.44-0.84, P=0.003). Moreover, rs1194338 was decreased associated with cancer susceptibility (A vs C: OR=0.89, 95%CI=0.80-0.98, P=0.01; AA vs CC: OR=0.77, 95%CI=0.62-0.96, P=0.02; AA+AC vs CC: OR=0.87, 95%CI=0.77-1.00, P=0.04; AA vs AC+CC: OR=0.82, 95%CI=0.67-1.00, P=0.05).Conclusion: Our results suggest that rs619586 and rs1194338 are associated with decreased cancer risk, while rs3200401 and rs664589 correlated with increased digestive cancer risk.


Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1150 ◽  
Author(s):  
Mohammad Hashemi ◽  
Shima Karami ◽  
Sahel Sarabandi ◽  
Abdolkarim Moazeni-Roodi ◽  
Andrzej Małecki ◽  
...  

A number of case-control studies regarding the association of the polymorphisms in the programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) genes with the risk of cancer have yielded inconsistent findings. Therefore, we have conducted a comprehensive, updated meta-analysis study to identify the impact of PD-1 and PD-L1 polymorphisms on overall cancer susceptibility. The findings revealed that PD-1 rs2227981 and rs11568821 polymorphisms significantly decreased the overall cancer risk (Odds Ratio (OR) = 0.82, 95% CI = 0.68–0.99, p = 0.04, TT vs. CT+CC; OR = 0.79, 95% CI = 0.67–0.94, p = 0.006, AG vs. GG, and OR = 0.82, 95% CI = 0.70–0.96, p = 0.020, AG+AA vs. GG, respectively), while PD-1 rs7421861 polymorphism significantly increased the risk of developing cancer (OR = 1.16, 95% CI = 1.02–1.33, p = 0.03, CT vs. TT). The PD-L1 rs4143815 variant significantly decreased the risk of cancer in homozygous (OR = 0.62, 95% CI = 0.41–0.94, p = 0.02), dominant (OR = 0.70, 95% CI = 0.50–0.97, p = 0.03), recessive (OR = 0.76, 95% CI = 0.60–0.96, p = 0.02), and allele (OR = 0.78, 95% CI = 0.63–0.96, p = 0.02) genetic models. No significant association between rs2227982, rs36084323, rs10204525, and rs2890658 polymorphisms and overall cancer risk has been found. In conclusions, the results of this meta-analysis have revealed an association between PD-1 rs2227981, rs11568821, rs7421861, as well as PD-L1 rs4143815 polymorphisms and overall cancer susceptibility.


2019 ◽  
Author(s):  
Xin-yuan Zhang ◽  
Xiao-han Wei ◽  
Bao-jie Wang ◽  
Jun Yao

Abstract Background The growing studies reports that the genes participating in repairing of DNA double-strand breaks may be cancer-susceptibility genes. Rs1805377 (A>G) is a functional single nucleotide polymorphism (SNP) in the x-ray cross-complementing group 4 (XRCC4) gene that may be involved in the etiology of cancer. However, no conclusive results can be determined from individually published studies. Thus, we performed a meta-analysis to examine the association between XRCC4 rs1805377 polymorphism and cancer risk.Methods The potential literatures were searched using three online electronic databases (PubMed, Embase, and Web of Science). The available studies were included according to the inclusion criteria. The pooled analysis were performed to explore the association between XRCC4 rs1805377 locus and the risk of cancer. Additionally, we also performed subgroup analysis and sensitivity analysis.Results Twenty-three studies were included in our meta-analysis. It contained 9,433 cancer patients and 10,337 healthy controls. The pooled results showed that there was no association between rs1805377 and the risk of cancer. Under the dominant model, the final pooled odds ratios (ORs) was 1.115 (95% confidence intervals: 0.956-1.301; P = 0.165) in a random effects model without the statistical significance. The subgroup analysis by ethnicity and source of controls also didn’t find that rs1805377 polymorphism was related to cancer occurrence. In the subgroup by type of cancers, the significant association was only found in gastric antrum adenocarcinoma.Conclusions our meta-analysis suggested that there was no association between rs1805377 polymorphism and cancer occurrence. It may provide useful information for the relevant studies on the etiology of cancer in future.


2019 ◽  
Vol 39 (12) ◽  
Author(s):  
Guowen Ding ◽  
Yu Chen ◽  
Huiwen Pan ◽  
Hao Qiu ◽  
Weifeng Tang ◽  
...  

Abstract Background: Previous case–control studies have suggested that apurinic/apyrimidinic endonuclease 1 (APE1) rs1760944 T>G polymorphism may be associated with cancer risk. Here, we carried out an updated meta-analysis to focus on the correlation between APE1 rs1760944 T>G locus and the risk of cancer. Methods: We used the crude odds ratios (ORs) with their 95% confidence intervals (CIs) to evaluate the possible relationship between the APE1 rs1760944 T>G polymorphism and cancer risk. Heterogeneity, publication bias and sensitivity analysis were also harnessed to check the potential bias of the present study. Results: Twenty-three independent studies involving 10166 cancer cases and 11598 controls were eligible for this pooled analysis. We found that APE1 rs1760944 T>G polymorphism decreased the risk of cancer in four genetic models (G vs. T: OR, 0.87; 95% CI, 0.83–0.92; P<0.001; GG vs. TT: OR, 0.77; 95% CI, 0.69–0.86; P<0.001; GG/TG vs. TT: OR, 0.83; 95% CI, 0.77–0.89, P<0.001 and GG vs. TT/TG: OR, 0.85; 95% CI, 0.80–0.92, P<0.001). Results of subgroup analyses also demonstrated that this single-nucleotide polymorphism (SNP) modified the risk among lung cancer, breast cancer, osteosarcoma, and Asians. Evidence of publication bias was found in the present study. When we treated the publication bias with ‘trim-and-fill’ method, the adjusted ORs and CIs were not significantly changed. Conclusion: In conclusion, current evidence highlights that the APE1 rs1760944 T>G polymorphism is a protective factor for cancer susceptibility. In the future, case–control studies with detailed risk factors are needed to confirm or refute our findings.


2021 ◽  
Author(s):  
Peng Yuan ◽  
Yudi Chen ◽  
Youzhao Ma ◽  
Chengjuan Zhang ◽  
Pengfei Ren ◽  
...  

Abstract Background Originally detected in breast cancer tissue, MMP-13 has been showed to be closely related to cancer development. Increasing evidence has also suggested that rs2252070, one of its SNP, can profoundly influence cancer risk by regulating the expression while the conclusion still remained controversial. Therefore, this meta-analysis was conducted to assess the carcinogenesis effect of this SNP quantitatively. Methods Studies about association between rs2252070 polymorphism and cancer risk by March 15, 2020 had been collected in PubMed, Web of Science, Cochrane Library and CNKI. R scripts and STATA software were applied to calculate estimates. Pooled ORs and corresponding 95% CIs were used to evaluate the strength of association. Results Twenty studies meeting pre-defined criteria were retrieved for the final statistical analysis, including 8,215 cancer patients and 8,480 healthy controls. The pooled estimates revealed no statistical significance for the association between this polymorphism and the risk of cancer in all 5 genetic models. Similarly, no significance had been detected in stratified analyses by region, cancer type, sample size and genotyping method. Conclusion The association between MMP-13 rs2252070 and carcinogenesis was not statistically significant. To elucidate this conclusion, future studies including gene-gene and gene-environment interaction are needed to verify the study results.


2019 ◽  
pp. 030006051989566 ◽  
Author(s):  
Jianguo Wang ◽  
Huaxiang Shen ◽  
Huijun Liang

Objective The purpose of this study was to systematically evaluate the association between methyl-CpG binding domain 4, DNA glycosylase ( MBD4) Glu346Lys polymorphism and cancer risk. Methods A comprehensive document retrieval from the Chinese National Knowledge Infrastructure (CNKI), EMBASE, and PubMed databases was performed through 1 September 2019. The strength of the correlation was assessed using the pooled odds ratio (ORs) and 95% confidence interval (CIs). Results Five relevant studies were retrieved following screening, including 1804 cases and 2193 controls. We found no association between MBD4 Glu346Lys polymorphism and cancer risk under all genetic models. Nevertheless, a subgroup analysis based on country showed a strong association in the Chinese population. Under the recessive model, Chinese individuals with the Lys/Lys genotype had a higher risk of cancer (OR = 1.37, 95% CI = 1.11–1.70). Conclusion Analysis of the MBD4 Glu346Lys polymorphism in different populations will help to elucidate the pathogenesis of cancer. The polymorphism can be utilized as a biomarker for cancer susceptibility among Chinese people.


2021 ◽  
Vol 36 (2) ◽  
pp. 172460082110338
Author(s):  
Yaxuan Wang ◽  
Zhan Yang ◽  
Xueliang Chang ◽  
Jingdong Li ◽  
Zhenwei Han

Purpose The study aims to provide a comprehensive account of the association of five MDM4 gene polymorphisms (rs1380576, rs1563828, rs10900598, rs11801299, and rs4245739) with susceptibility to cancer. Methods A literature search for eligible candidate gene studies published before 27 February 2021 was conducted in PubMed, Medline and Web of Science. The following combinations of main keywords were used: (MDM4 OR MDMX OR HDMX OR mouse double minute 4 homolog) AND (polymorphism OR mutation OR variation OR SNP OR genotype) AND (cancer OR tumor OR neoplasm OR malignancy OR carcinoma OR adenocarcinoma). Potential sources of heterogeneity were sought out via meta-regression, subgroup and sensitivity analysis. Results Overall, a total of 15 articles with 21,365 cases and 29,280 controls for five polymorphisms of the MDM4 gene were enrolled. In the stratified analysis of rs1380576, we found that Asians might have less susceptibility to cancer. We found that rs4245739 was correlated with a decreased risk of cancer for Asians and breast cancer susceptibility. However, for other polymorphisms, the results showed no significant association with cancer risk. Conclusion MDM4 rs1380576 polymorphism is negatively associated with the risk of cancer in the Asian population. MDM4 rs4245739 polymorphism is inversely associated with cancer risk for Asians and breast cancer susceptibility.


2019 ◽  
Vol 39 (6) ◽  
Author(s):  
Xiaoxia He ◽  
Peng Wang ◽  
Ying Li ◽  
Na Shen

AbstractRs189037 (G>A) is an important functional variant with ataxia telangiectasia mutated (ATM) gene, which might affect ATM’s expression involvement in several human cancers. Increasing evidence reveals that smoking-related cancers have distinct molecular characteristics from non-smoking cancers. Until now, the role of ATM rs189037 in cancer risk stratified by smoking status still remains unclear. To evaluate the association between ATM rs189037 and cancer risk based on smoking status, we performed this meta-analysis by a comprehensive literature search via databases of PubMed, Embase, Web of Science and CNKI, updated till January 2019. Multivariate-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were extracted from eligible studies if available, to assess the relationship strengths. A total of seven eligible studies were included, comprising 4294 cancer patients (smokers: 1744 [40.6%]) and 4259 controls (smokers: 1418 [33.3%]). Results indicated a significant association of ATM rs189037 with cancer risk. In non-smokers, compared with GG genotype, AA genotype increased a 1.40-fold risk of overall cancer (OR = 1.40, 95% CI = 1.15–1.70, Pheterogeneity=0.433, I2 = 0.0%). Subgroup analysis in lung cancer (LC) also exhibited a significant result (OR = 1.41, 95% CI = 1.15–1.73, Pheterogeneity=0.306, I2 = 17.0%) only in non-smokers. However, the association was not observed in smokers, no matter for overall cancer or for LC. Our findings highlight that ATM rs189037 significantly increases cancer susceptibility in non-smokers, rather than in smokers. The association is prominent in LC.


2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Xue Wang ◽  
Jialing Zhong ◽  
Fang Chen ◽  
Kang Hu ◽  
Suhong Sun ◽  
...  

Abstract Background We have performed this study to evaluate the association between H19 rs217727 polymorphism and the risk of cancer. Methods An odds ratio (OR) with a 95% confidence interval (CI) was applied to determine a potential association. Results A total of 17 case–control publications were selected. This meta-analysis showed that H19 rs217727 has a significant increased association with cancer risk in allelic, homozygous, heterozygote, dominant and recessive models (T vs C: OR = 1.16, 95% CI = 1.06–1.27, I2 = 75.7; TT vs CC: OR = 1.29, 95% CI = 1.06–1.56, I2 = 71.6; CT vs CC: OR = 1.15, 95% CI = 1.01–1.31, I2 = 75.4; CT + TT vs CC: OR = 1.20, 95% CI = 1.05–1.36, I2 = 76.5; TT vs CT + CC: OR = 1.22, 95% CI = 1.02–1.45, I2 = 70.6;). In the subgroup analysis of smoking status, both smokers and nonsmokers showed an increase in cancer risk in allelic, homozygous, dominant and heterozygote models. Conclusion This meta-analysis revealed H19 rs217727 may influence cancer susceptibility.


Sign in / Sign up

Export Citation Format

Share Document